Pinebridge Investments L.P. Cuts Position in DaVita Inc. (NYSE:DVA)

Pinebridge Investments L.P. decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,294 shares of the company's stock after selling 7,622 shares during the period. Pinebridge Investments L.P. owned about 0.13% of DaVita worth $15,597,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in shares of DaVita in the fourth quarter valued at approximately $41,000. Canada Post Corp Registered Pension Plan purchased a new position in DaVita in the 4th quarter valued at approximately $55,000. Venturi Wealth Management LLC grew its stake in shares of DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares in the last quarter. Versant Capital Management Inc increased its position in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares during the period. Finally, Blue Trust Inc. boosted its holdings in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after purchasing an additional 131 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on DVA. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $166.33.

DaVita Stock Performance

Shares of NYSE DVA traded up $0.01 during trading hours on Friday, reaching $139.57. The stock had a trading volume of 600,714 shares, compared to its average volume of 841,722. The firm has a market cap of $11.17 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 1.07 and a beta of 1.04. DaVita Inc. has a fifty-two week low of $131.27 and a fifty-two week high of $179.60. The firm has a 50-day moving average of $146.50 and a 200-day moving average of $155.27. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.